<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00255086</url>
  </required_header>
  <id_info>
    <org_study_id>95722</org_study_id>
    <nct_id>NCT00255086</nct_id>
  </id_info>
  <brief_title>The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients</brief_title>
  <official_title>The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients: A Randomized, Placebo-Controlled, 52-Week Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Palo Alto Veterans Institute for Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the proposed study is to determine if the NMDA receptor antagonist memantine has a
      neuroprotective effect on magnetic resonance spectroscopic imaging (MRS) measures of brain
      NAA and magnetic resonance imaging (MRI) volumetric measures of hippocampal volume. In
      secondary analyses, we will determine if measures of clinical stabilization produced by
      memantine in the treatment of Alzheimer's disease (AD) parallels stabilization of MRS
      measures of brain NAA and MRI volumetric measures of hippocampal volume.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alzheimer's disease (AD) is the most common form of dementia. Currently, there are more than
      4 million individuals with dementia in the United States with at least 400,000 deaths
      annually. AD is a progressive, neurodegenerative disorder, characterized neuropathologically
      by widespread neuronal loss, presence of neurofibrillary tangles, and deposits of beta
      amyloid in cerebral blood vessels and neuritic plaques. Since the medial-temporal lobes,
      hippocampus, and association cortex are significantly impacted it is not surprising that the
      primary symptom of AD is a decline in cognitive functioning that leads to marked impairment
      in daily functioning. In particular, memory impairments, visuospatial decline, language
      difficulties, and loss of executive function are central cognitive symptoms of this illness.
      Behavioral disturbances such as agitation and hallucinations often accompany disease
      progression. The illness lasts approximately 7 to 10 years, with patients requiring total
      care in the latter stages. Thus, AD places a tremendous emotional and economic burden on both
      patients and their caregivers. Beyond a cure, therapeutic approaches which would alleviate
      the symptoms or delay progression could be of substantial psychological and economic benefit.
      Recent placebo controlled clinical trials have shown memantine to be efficacious in the
      treatment of patients with moderate to severe AD.

      The aim of the proposed study is to determine if the NMDA receptor antagonist memantine has a
      neuroprotective effect on magnetic resonance spectroscopic imaging (MRS) measures of brain
      NAA and magnetic resonance imaging (MRI) volumetric measures of hippocampal volume. In
      secondary analyses, we will determine if measures of clinical stabilization produced by
      memantine in the treatment of Alzheimer's disease (AD) parallels stabilization of MRS
      measures of brain NAA and MRI volumetric measures of hippocampal volume.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NAA/Cr Ratio</measure>
    <time_frame>Baseline; Year 1</time_frame>
    <description>To determine if memantine has a neuroprotective effect on magnetic resonance spectroscopic imaging (MRS) measures of hippocampal n-acetyl aspartate (NAA) and magnetic resonance imaging volumetric measures (MRI) of hippocampal volume.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change on the ADAS-Cog Score After 1 Year</measure>
    <time_frame>Baseline; Year 1</time_frame>
    <description>Progression of cognitive functioning as measured by performance on the Alzheimer's Disease (AD) Assessment Scale-cognitive subscale (ADAS-Cog). ADAS-cog is the most popular cognitive testing instrument used in clinical trials of nootropics, and measures disturbances of of memory, language, praxis, attention and other cognitive abilities which are often referred to as the core symptoms of AD. Responses are summed for an overall score which can range from 0-70. The greater the dysfunction, the higher the score. A typical score for a person without dementia is 5.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Memantine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg Memantine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 mg Placebo pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <description>10mg Memantine</description>
    <arm_group_label>Memantine</arm_group_label>
    <other_name>Namenda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pill</intervention_name>
    <description>10mg placebo pill</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:1. Dementia criteria by DSM-IV.

        2. 50-95 years of age inclusive.

        3. MMSE at screen and baseline 7-28 inclusive.

        4. Conversant in English.

        5. Caregiver/study partner willing to participate, supervise the patient and be available
        for administration of study medication.

        6. Able to ingest oral medication.

        Exclusion Criteria:1. History of clinically significant stroke without substantial
        recovery.

        2. Neurological or medical conditions causing significant disability independent of
        dementia.

        3. Parkinson's disease.

        4. History in past two years of focal brain lesion, head injury with loss of consciousness
        or DSM-IV criteria for any major psychiatric disorder including psychosis, major
        depression, bipolar disorder, alcohol or substance abuse.

        5. Dementia due to Korsakoff's syndrome or infectious diseases such as Creutzfeldt-Jakob
        disease, herpes, encephalitis, or human immunodeficiency virus.

        6. Sensory impairment that would prevent subject from participating in or cooperating with
        the protocol.

        7. Significant clinical disorder or laboratory finding that renders the subject unsuitable
        for receiving an investigational drug including: clinically significant or unstable
        hematologic, hepatic, cardiovascular, pulmonary, gastrointestinal, endocrine, metabolic,
        renal, or other systemic disease or laboratory abnormality.

        8. Clinical contraindication to the use of memantine (e.g., hypersensitivity).

        9. History of seizure within past 5 years prior to screening.

        10. Platelet count &lt; 100,000/mm3.

        11. History of claustrophobia

        12. Presence of metallic implants such as pacemakers, surgical aneurysm clips, or known
        metal fragments embedded in the body
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Wesson Ashford Jr., MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerome A Yesavage</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2005</study_first_submitted>
  <study_first_submitted_qc>November 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2005</study_first_posted>
  <results_first_submitted>August 23, 2016</results_first_submitted>
  <results_first_submitted_qc>February 23, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 7, 2017</results_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Jerome A Yesavage,</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>17 subjects were randomized. All subjects had completed all participation by October, 2008. All were recruited at VA Palo Alto Health Care System.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Memantine</title>
          <description>10mg Memantine
Memantine</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Participants were given Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Per protocol, only participants who completed the study were evaluable for baseline characteristics.</population>
      <group_list>
        <group group_id="B1">
          <title>Memantine</title>
          <description>10mg Memantine
Memantine</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>10mg Placebo pill</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.5" lower_limit="50" upper_limit="90"/>
                    <measurement group_id="B2" value="75.4" lower_limit="50" upper_limit="90"/>
                    <measurement group_id="B3" value="75.9" lower_limit="50" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>NAA/Cr Ratio</title>
        <description>To determine if memantine has a neuroprotective effect on magnetic resonance spectroscopic imaging (MRS) measures of hippocampal n-acetyl aspartate (NAA) and magnetic resonance imaging volumetric measures (MRI) of hippocampal volume.</description>
        <time_frame>Baseline; Year 1</time_frame>
        <population>Participants who could tolerate study medication and who completed the study were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Memantine</title>
            <description>10mg Memantine
Memantine</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants were given Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>NAA/Cr Ratio</title>
          <description>To determine if memantine has a neuroprotective effect on magnetic resonance spectroscopic imaging (MRS) measures of hippocampal n-acetyl aspartate (NAA) and magnetic resonance imaging volumetric measures (MRI) of hippocampal volume.</description>
          <population>Participants who could tolerate study medication and who completed the study were included in the analysis.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0.11"/>
                    <measurement group_id="O2" value="1.38" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.14"/>
                    <measurement group_id="O2" value="1.41" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change on the ADAS-Cog Score After 1 Year</title>
        <description>Progression of cognitive functioning as measured by performance on the Alzheimer's Disease (AD) Assessment Scale-cognitive subscale (ADAS-Cog). ADAS-cog is the most popular cognitive testing instrument used in clinical trials of nootropics, and measures disturbances of of memory, language, praxis, attention and other cognitive abilities which are often referred to as the core symptoms of AD. Responses are summed for an overall score which can range from 0-70. The greater the dysfunction, the higher the score. A typical score for a person without dementia is 5.</description>
        <time_frame>Baseline; Year 1</time_frame>
        <population>Participants who could tolerate study medication and who completed the study were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Memantine</title>
            <description>10mg Memantine
Memantine</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>10mg Placebo pill</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change on the ADAS-Cog Score After 1 Year</title>
          <description>Progression of cognitive functioning as measured by performance on the Alzheimer's Disease (AD) Assessment Scale-cognitive subscale (ADAS-Cog). ADAS-cog is the most popular cognitive testing instrument used in clinical trials of nootropics, and measures disturbances of of memory, language, praxis, attention and other cognitive abilities which are often referred to as the core symptoms of AD. Responses are summed for an overall score which can range from 0-70. The greater the dysfunction, the higher the score. A typical score for a person without dementia is 5.</description>
          <population>Participants who could tolerate study medication and who completed the study were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.67" spread="10.30"/>
                    <measurement group_id="O2" value="49.17" spread="8.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.75" spread="7.99"/>
                    <measurement group_id="O2" value="50.39" spread="8.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Memantine</title>
          <description>10mg Memantine</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Participants were given matching placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrythmia</sub_title>
                <description>Not related to study medication; incident occurred before medication was started; family notified researcher of problem and subject withdrawn.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>complications due to type II diabetes</sub_title>
                <description>Not related to study medication (on placebo). Hospitalized, withdrawn from study. Later died.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Crohnâ€™s disease flare-ups</sub_title>
                <description>Not related to study medication (subject was on placebo). Notified by patient. Hospitalized, treated and released, continued with study.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Tattoo eyeliner</sub_title>
                <description>Study requirement is MRI. Unable to complete study procedures due to tattoo eyeliner so subject was withdrawn by the PI. Not study related.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Lethargy</sub_title>
                <description>Subject discontinued medication and was terminated from the trial by the PI.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <description>Subject discontinued medication and was terminated from the trial by the PI.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Study medication non compliance</sub_title>
                <description>Subject discontinued medication and was terminated from the trial by the PI.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wes Ashford, PhD, MD</name_or_title>
      <organization>VA Palo Alto Health Care System</organization>
      <phone>650-493-5000</phone>
      <email>wes.ashford@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

